This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Réa D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138:2031–41. https://doi.org/10.1182/blood.2020009984.
Schmidt S, Liu Y, Hu ZH, Williams KM, Lazarus HM, Vij R, et al. The role of donor lymphocyte infusion (DLI) in post-hematopoietic cell transplant (HCT) relapse for chronic myeloid leukemia (CML) in the tyrosine kinase inhibitor (TKI) era. Biol Blood Marrow Transplant. 2020;26:1137–43. https://doi.org/10.1016/j.bbmt.2020.02.006.
DeFilipp Z, Ancheta R, Liu Y, Hu ZH, Gale RP, Snyder D, et al. Maintenance tyrosine kinase inhibitors following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia: a Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2020;26:472–9. https://doi.org/10.1016/j.bbmt.2019.10.017.
DeFilipp Z, Langston AA, Chen Z, Zhang C, Arellano ML, El Rassi F, et al. Does post-transplant maintenance therapy with tyrosine kinase inhibitors improve outcomes of patients with high-risk Philadelphia chromosome-positive leukemia? Clin Lymphoma Myeloma Leuk. 2016:466–71.e1. https://doi.org/10.1016/j.clml.2016.04.017.
Chalandon Y, Passweg JR, Guglielmi C, Iacobelli S, Apperley J, Schaap NP, et al. Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT. Haematologica. 2014;99:1492–8. https://doi.org/10.3324/haematol.2013.100198.
Petrungaro A, Gentile M, Mazzone C, Greco R, Uccello G, Recchia AG, et al. Ponatinib-induced graft-versus-host disease/graft-versus-leukemia effect in a patient with Philadelphia-positive acute lymphoblastic leukemia without the T315I mutation relapsing after allogeneic transplant. Chemotherapy. 2017;62:353–6. https://doi.org/10.1159/000477714.
Renzi D, Marchesi F, De Angelis G, Elia L, Salvatorelli E, Gumenyuk S, et al. Rome Transplant Network. Ponatinib induces a persistent molecular response and graft-versus-host disease/graft-versus-leukemia effect in a patient with Philadelphia-positive acute lymphoblastic leukemia with a T315I mutation following early relapse after allogeneic transplant. Chemotherapy. 2017;62:58–61. https://doi.org/10.1159/000448750.
Carpenter PA, Snyder DS, Flowers ME, Sanders JE, Gooley TA, Martin PJ, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood. 2007;109:2791–3. https://doi.org/10.1182/blood-2006-04-019836.
Ram R, Storb R, Sandmaier BM, Maloney DG, Woolfrey A, Flowers ME, et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica. 2011;96:1113–20. https://doi.org/10.3324/haematol.2011.040261.
Eadie LN, Saunders VA, Branford S, White DL, Hughes TP. The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro. Oncotarget. 2018;9:13423–37. https://doi.org/10.18632/oncotarget.24393.
Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381:2315–26. https://doi.org/10.1056/NEJMoa1902328.
JFA and DM are grateful for the support of the Imperial College National Institute of Health Research (NIHR) Biomedical Research Centre and Blood Cancer UK Vaccine Research Collaborative, a partnership between Blood Cancer UK, Myeloma UK, Anthony Nolan and the British Society of Haematology (Grant 21011).
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Fernando, F., Innes, A.J., Claudiani, S. et al. The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia. Bone Marrow Transplant 58, 826–828 (2023). https://doi.org/10.1038/s41409-023-01975-9